The treatment of phenols waters resulted from a petrochemical platform was studied. The purpose of this work was to determine if the Haldane model fit to the real process. The biodegradation time was determined by Haldane model in different conditions of initial phenols concentrations and was compared with the experimental biodegradation time. The Haldane equation µ=µm cS/(( KS + cS + (cS 2/Ki)) with kinetics constants KS=6.19 mg•l-1, Ki=54.1

The treatment of phenolic waters resulted from a petrochemical platform was studied. The purpose of this work was to simulate the real industrial process under the Monod model and to determine if the model fits with the real process. The Monod model used to simulate the industrial process was based on equation Jarzebski et al. The biodegradation time was determined by the model at an initial phenols concentration of 23.4 mg•l-1 and using pure cultures

The paper presents the experimental research to redesign the separation stage of a bacterial immunomodulator of pharmaceutical use, to be integrated into the GMP (Good Manufacturing Practice) small scale bio product manufacture aseptic, closed flow. It is to study the separation characteristics for each technological operation, the membrane regeneration capacity and to evaluate the period of working time.

The technological solutions were elaborated to achieve design of the production flow with respect of the Good Manufacturing Practice (GMP) guidelines. To be in line with the GMP rules a fed-batch operation mode is be designed based on the batch modelling results. As the production rate of the microbial immunomodulator is associated with the biomass growth rate, it was to study the bacterium growth kinetics in batch process. After the selection of

The aim of this paper is to study the growth kinetics of a strain of Pseudomonas aeruginosa feeding on peptone under aerobic conditions. This is a part of a larger experimental project dealing with the optimisation of a preparation process of an immunomodulator product extracted from the harvested cells. The therapeutic effect was evaluated by protecting activity against bacterial infection on mice. The experiments were conducted in a bottom driven

Chapter 1 highlights the current state of the art regarding the content and the application of the Good Manufacturing Practice rules for the manufacture of the therapeutic bioproducts of human use. They must be also observed by the romanian biopharmaceuticals companies after the accession into the European Union. These rules are to be applied to all stages of the technological flow, and they impose the need of research in connection with: (a) the